The Exscalate4Cov project, which involves 15 partners (including Uni Basel and the Swiss Institute for Informatics) and 18 external supporters (including the Biozentrum, Dept. Pharmaceutical science and your beloved Innovation Office - yay!) had a first outcome!
The supercomputers identified Raloxifene as effective against SARS-NCoV-2 and in-vitro testing confirmed it: now it was proposed for a clinical trial phase. Below you can find the President of EU Commission Ursula von der Leyen talking about the project.
European Commission Article & Video: